Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.

ABSTRACT:

Background

While immediate benefits of levodopa-carbidopa intestinal gel (LCIG) are evident in patients with Parkinson's disease (PD), long-term LCIG effects require further study.

Objectives

We explored long-term LCIG on motor symptoms, nonmotor symptoms (NMS), and LCIG treatment settings in patients with advanced PD (APD).

Methods

Data were obtained (medical records and patient visit) from COSMOS, a multinational, retrospective, cross-sectional post-marketing observational study in patients with APD. Patients were stratified into 5 groups based on LCIG treatment duration at the patient visit, from 1-2 to > 5 years LCIG. Between-group differences were assessed for changes from baseline in LCIG settings, motor symptoms, NMS, add-on medications, and safety.

Results<

SUBMITTER: Fasano A 

PROVIDER: S-EPMC10130122 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature